Search hospitals

>

Hawaii

>

Honolulu

Kapiolani Medical Center for Women and Children

Claim this profile

Honolulu, Hawaii 96826

Global Leader in Cancer

Global Leader in Breast Cancer

Conducts research for Lung Cancer

Conducts research for Ovarian Cancer

Conducts research for Breast cancer

420 reported clinical trials

16 medical researchers

Photo of Kapiolani Medical Center for Women and Children in HonoluluPhoto of Kapiolani Medical Center for Women and Children in HonoluluPhoto of Kapiolani Medical Center for Women and Children in Honolulu

Summary

Kapiolani Medical Center for Women and Children is a medical facility located in Honolulu, Hawaii. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Breast cancer and other specialties. Kapiolani Medical Center for Women and Children is involved with conducting 420 clinical trials across 644 conditions. There are 16 research doctors associated with this hospital, such as Wade T. Kyono, Jeffrey L. Berenberg, Jared D. Acoba, and Jami A. Fukui.

Area of expertise

1

Cancer

Global Leader

Kapiolani Medical Center for Women and Children has run 79 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage I
Stage II
2

Breast Cancer

Global Leader

Kapiolani Medical Center for Women and Children has run 70 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
HER2 negative
ER positive

Top PIs

Clinical Trials running at Kapiolani Medical Center for Women and Children

Breast Cancer

Cancer

Lung Cancer

Ovarian Cancer

Breast cancer

Pancreatic Cancer

Brain Tumor

Testicular cancer

Burkitt Lymphoma

Leukemia

Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.

Recruiting

2 awards

Phase 3

19 criteria

Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are being observed for cardiac toxicity. The largest cohort (currently open to accrual) is observational, and contains patients who are taking a beta blocker, ACE inhibitor, or ARB as well as their trastuzumab-based treatment. The goal is to understand how common cardiac problems are in this group of patients at high risk. The smaller cohort (currently closed to accrual) is randomized. Patients in this second cohort are randomized to either carvedilol or no treatment, with the goal of seeing whether carvedilol (used to treat heart failure and high blood pressure) may prevent the heart from side effects of chemotherapy.

Recruiting

2 awards

Phase 3

23 criteria

Image of trial facility.

Radiation and HER2-Targeted Therapy

for Breast Cancer

This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.

Recruiting

2 awards

Phase 3

15 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Kapiolani Medical Center for Women and Children?

Where is Kapiolani Medical Center for Women and Children located?

Who should I call to ask about financial aid or insurance network?

What insurance does Kapiolani Medical Center for Women and Children accept?

What awards or recognition has Kapiolani Medical Center for Women and Children received?